BioPharmSignal logoBioPharmSignal

Biotech News

Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting

Nektar Therapeutics (NKTR)Nektar Therapeutics2026-06-25 13:46 ESTClinical readout

SAN FRANCISCO, March 20, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that data from the ongoing Phase 2b studies of rezpegaldesleukin in atopic dermatitis and alopecia areata have been accepted for two oral presentations at the 2026 American Academy of Dermatology (AAD)

Open original release

Related news

NKTRNektar Therapeutics2026-06-25 13:46 EST

Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York

NKTRNektar Therapeutics2026-06-25 13:46 EST

Nektar Therapeutics Reports First Quarter 2026 Financial Results

NKTRNektar Therapeutics2026-06-25 13:46 EST

Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

NKTRNektar Therapeutics2026-06-25 13:46 EST

Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting

NKTRNektar Therapeutics2026-06-25 13:46 EST

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NKTRNektar Therapeutics2026-06-25 13:46 EST

Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets

NKTRNektar Therapeutics2026-06-25 13:46 EST

Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

NKTRNektar Therapeutics2026-06-25 13:46 EST

Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering

NKTRNektar Therapeutics2026-06-25 13:46 EST

Nektar Therapeutics Announces Proposed Public Offering

NKTRNektar Therapeutics2026-06-25 13:46 EST

52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin

View all latest news

Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

NKTRNektar Therapeutics2026-06-26 07:18 EST

Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York

NKTRNektar Therapeutics2026-06-26 07:18 EST

Nektar Therapeutics Reports First Quarter 2026 Financial Results

NKTRNektar Therapeutics2026-06-26 07:18 EST

Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

NKTRNektar Therapeutics2026-06-26 07:18 EST

Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting

NKTRNektar Therapeutics2026-06-26 07:18 EST

Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States